Albireo Pharma, Inc. (ALBO)
(Delayed Data from NSDQ)
$36.36 USD
+1.29 (3.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $36.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ALBO 36.36 +1.29(3.68%)
Will ALBO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALBO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALBO
Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Tops Revenue Estimates
ALBO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?
Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates